Acor investor alert: law offices of howard g. smith continues investigation on behalf of acorda therapeutics, inc. investors

Bensalem, pa.--(business wire)--law offices of howard g. smith continues its investigation on behalf of acorda therapeutics, inc. (“acorda” or the “company”) (nasdaq: acor) investors concerning the company and its officers’ possible violations of federal securities laws. on november 15, 2017, acorda announced that five patients enrolled in a late stage trial of tozadenant, a treatment for parkinson’s, had died. on this news, acorda’s share price fell $11.20, or 39.7%, to close at $17.00 on november 15, 2017, thereby injuring investors. if you purchased acorda securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact howard g. smith, esquire, of law offices of howard g. smith, 3070 bristol pike, suite 112, bensalem, pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
ACOR Ratings Summary
ACOR Quant Ranking